41 related articles for article (PubMed ID: 19360342)
21. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.
Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Higuchi T; Miyakubo M; Ishikita T; Nakajima T; Endo K
Ann Nucl Med; 2008 Jan; 22(1):83-6. PubMed ID: 18250992
[TBL] [Abstract][Full Text] [Related]
23. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma.
Seo S; Hatano E; Higashi T; Hara T; Tada M; Tamaki N; Iwaisako K; Ikai I; Uemoto S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):427-33. PubMed ID: 17255262
[TBL] [Abstract][Full Text] [Related]
24. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
25. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.
Zhao S; Kuge Y; Mochizuki T; Takahashi T; Nakada K; Sato M; Takei T; Tamaki N
J Nucl Med; 2005 Apr; 46(4):675-82. PubMed ID: 15809491
[TBL] [Abstract][Full Text] [Related]
26. FDG accumulation and tumor biology.
Pauwels EK; Ribeiro MJ; Stoot JH; McCready VR; Bourguignon M; Mazière B
Nucl Med Biol; 1998 May; 25(4):317-22. PubMed ID: 9639291
[TBL] [Abstract][Full Text] [Related]
27. Influence of chemoresistance and p53 status on fluoro-2-deoxy-D-glucose incorporation in cancer.
Smith TA
Nucl Med Biol; 2010 Jan; 37(1):51-5. PubMed ID: 20122668
[TBL] [Abstract][Full Text] [Related]
28. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.
Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Kitamura K; Ikai I; Uemoto S
Int J Oncol; 2009 May; 34(5):1303-12. PubMed ID: 19360342
[TBL] [Abstract][Full Text] [Related]
29. Cancer Metabolism as a Mechanism of Treatment Resistance and Potential Therapeutic Target in Hepatocellular Carcinoma.
Lee M; Ko H; Yun M
Yonsei Med J; 2018 Dec; 59(10):1143-1149. PubMed ID: 30450847
[TBL] [Abstract][Full Text] [Related]
30. Positron emission tomography diagnostic imaging in multidrug-resistant hepatocellular carcinoma: focus on 2-deoxy-2-(18F)Fluoro-D-Glucose.
Brito AF; Mendes M; Abrantes AM; Tralhão JG; Botelho MF
Mol Diagn Ther; 2014 Oct; 18(5):495-504. PubMed ID: 24852041
[TBL] [Abstract][Full Text] [Related]
31. Current status of imaging biomarkers predicting the biological nature of hepatocellular carcinoma.
Yoneda N; Matsui O; Kobayashi S; Kitao A; Kozaka K; Inoue D; Yoshida K; Minami T; Koda W; Gabata T
Jpn J Radiol; 2019 Mar; 37(3):191-208. PubMed ID: 30712167
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
